Advances in histamine pharmacology reveal new drug targets.
This Themed Issue consists of three reviews and 11 original articles authored by internationally respected industrial and academic pharmacologists from across three continents. It derives from the highly successful symposium on 'The H3 and H4 histamine receptors: the antihistamines for the 21(st) century', which took place at EPHAR 2008 in Manchester University, and encompasses new roles, new compounds and exciting new therapeutic areas for histamine.
Paul L
PL
Chazot
D000818:Animals; D006633:Histamine Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D054828:Histamine H3 Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D006640:Histidine Decarboxylase / Q000037:antagonists & inhibitors; D006801:Humans; D008958:Models, Molecular; D043562:Receptors, G-Protein-Coupled / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D011968:Receptors, Histamine / Q000502:physiology*; D018100:Receptors, Histamine H3 / Q000502:physiology*; D000074040:Receptors, Histamine H4
C418607:HRH4 protein, human; D006633:Histamine Antagonists; D054828:Histamine H3 Antagonists; D043562:Receptors, G-Protein-Coupled; D011968:Receptors, Histamine; D018100:Receptors, Histamine H3; D000074040:Receptors, Histamine H4; D006640:Histidine Decarboxylase